Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG)Roswitha Forstpointner, Wolfgang Hiddemann, Michael Unterhalt et al.|Blood|2006Cited by 465
Stromal Antigen Targeting by a Humanised Monoclonal Antibody: An Early Phase II Trial of Sibrotuzumab in Patients with Metastatic Colorectal CancerRalf‐Dieter Hofheinz, G. Stehle, Salah‐Eddin Al‐Batran et al.|Oncology Research and Treatment|2003Cited by 364
Prediction of malignant middle cerebral artery infarction by magnetic resonance imaging within 6 hours of symptom onset: A prospective multicenter observational studyGötz Thomalla, Joachim Röther, Jan Felix Kersten et al.|Annals of Neurology|2010Cited by 248